{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(5)"],"submitter":["Furukawa K"],"pubmed_abstract":["<h4>Importance</h4>Although 2 and 3 doses of vaccine have been implemented against the SARS-CoV-2 pandemic, the level of immunity achieved by these additional vaccinations remains unclear.<h4>Objective</h4>To investigate the induction of neutralizing antibodies against the SARS-CoV-2 Omicron variant after 2 and 3 doses of the BNT162b2 messenger RNA (mRNA) vaccine among recipients of different ages.<h4>Design, setting, and participants</h4>A cohort study was conducted from June 1, 2021, to January 12, 2022, among 82 physicians at Kobe University Hospital who had received 2 doses of the BNT162b2 mRNA vaccine.<h4>Main outcomes and measures</h4>The rates of positive test results and the titers of neutralizing antibodies against the Omicron variant after 2 and 3 doses of the vaccine were compar"],"journal":["JAMA network open"],"pagination":["e2210780"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9086840"],"repository":["biostudies-literature"],"pubmed_title":["Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine."],"pmcid":["PMC9086840"],"pubmed_authors":["Furukawa K","Mori Y","Nishimura M","Arii J","Kurahashi Y","Sutandhio S","Tjan LH"],"additional_accession":[]},"is_claimable":false,"name":"Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.","description":"<h4>Importance</h4>Although 2 and 3 doses of vaccine have been implemented against the SARS-CoV-2 pandemic, the level of immunity achieved by these additional vaccinations remains unclear.<h4>Objective</h4>To investigate the induction of neutralizing antibodies against the SARS-CoV-2 Omicron variant after 2 and 3 doses of the BNT162b2 messenger RNA (mRNA) vaccine among recipients of different ages.<h4>Design, setting, and participants</h4>A cohort study was conducted from June 1, 2021, to January 12, 2022, among 82 physicians at Kobe University Hospital who had received 2 doses of the BNT162b2 mRNA vaccine.<h4>Main outcomes and measures</h4>The rates of positive test results and the titers of neutralizing antibodies against the Omicron variant after 2 and 3 doses of the vaccine were compar","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-05-09T23:39:41.165Z","creation":"2025-04-04T19:33:27.451Z"},"accession":"S-EPMC9086840","cross_references":{"pubmed":["35532938"],"doi":["10.1001/jamanetworkopen.2022.10780"]}}